Clinical trial
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing…
NCT00441103 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00441103 |
|---|---|
| Title | A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis |
| Official title | A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis |
| Acronym | IMPROVE |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Rebif® New Formulation (IFN-beta-1a, RNF), Placebo |
| Enrollment | 180 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Feb 28, 2007 |
| Last update posted | Jul 9, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: